Pleco Therapeutics is focused on developing innovative Plecoid™ therapies designed to enhance the effectiveness of existing cancer treatments, particularly in challenging cases such as Acute Myeloid Leukaemia (AML) and Small Cell Lung Cancer (SCLC). Their approach involves altering protein expression within the cancer microenvironment and addressing the accumulation of toxic metals in cancer cells. By utilizing chelating agents that selectively remove harmful metals while preserving essential ones, Pleco aims to improve patient outcomes and quality of life. The company has established a unique model system to study the interactions between sub-toxic metal accumulation and cancer, which is pivotal for advancing chelation therapy in metal-associated cancers.

The therapeutic pipeline at Pleco Therapeutics includes several products currently in preclinical and clinical development, with a lead compound undergoing clinical testing. Their research is particularly focused on optimizing formulations that target specific cancers, including leukemia, lung cancer, and pancreatic cancer. The company’s commitment to addressing the unmet needs in cancer treatment is underscored by the poor prognoses associated with AML and SCLC, where traditional therapies have seen limited success. By advancing their Plecoid™ therapies, Pleco Therapeutics aims to make significant strides in improving survival rates and treatment efficacy for patients suffering from these aggressive cancers.

Netherlands

Pleco Therapeutics is a specialty biopharmaceutical company developing novel combination chelating agents to detoxify the cancer microenvironment. Their Plecoid™ therapies positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals.

Pleco Therapeutics

Company Details